Search

Your search keyword '"Darryl Toth"' showing total 41 results

Search Constraints

Start Over You searched for: Author "Darryl Toth" Remove constraint Author: "Darryl Toth"
Sorry, I don't understand your search. ×
41 results on '"Darryl Toth"'

Search Results

1. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial

2. Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*

3. Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies

5. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

7. Améliorations à long terme chez les patients traités par tralokinumab souffrant de dermatite atopique modérée à sévère : analyse intermédiaire de l’étude ECZTEND

8. Long-Term Improvements Observed in Tralokinumab-Treated Patients with Moderate-to-Severe Atopic Dermatitis: an ECZTEND Interim Analysis

9. A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis

10. Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies

11. 208 Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies

12. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study

13. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis

14. 27874 Correlation of itch response to roflumilast cream with disease severity and patient-reported outcomes in patients with chronic plaque psoriasis

15. 27716 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline clinical characteristics: Pooled subgroup analysis from two randomized phase 3 studies

16. 27496 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline patient demographics: Pooled subgroup analysis from two randomized phase 3 studies

17. 27697 Long-term efficacy, safety, and adherence to tralokinumab treatment in moderate-to-severe atopic dermatitis for up to 3 years: Interim readout of ECZTEND, a phase 3, long-term extension trial

19. Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial

20. Roflumilast Cream (ARQ-151) Improved Itch Severity and Itch-Related Sleep Loss in Adults With Chronic Plaque Psoriasis in a Phase 2b Study

21. Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

22. Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies

23. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis

24. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population

25. A fixed-dose combination of adapalene 0.1%–BPO 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne

26. An Open Letter to Health Canada

27. Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study

28. Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies

29. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

30. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study

31. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

32. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

33. SKIN AND DIABETES

34. 054 Treatment with ixekizumab over 60 weeks provides sustained improvements in health-related quality of life: Results from UNCOVER-1, a randomized phase 3 trial

35. Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies

36. Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis

37. Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab

38. Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence

39. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis

40. Relapse, rebound, and psoriasis adverse events: an advisory group report

41. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis

Catalog

Books, media, physical & digital resources